Targeted delivery of small interfering RNA to angiogenic endothelial cells with liposome-polycation-DNA particles

Journal of Controlled Release

Volumn 160, Issue 2, 2012, Pages 211-216

  Vader, P ^a,b   Crielaard, B J ^a   Van Dommelen, S M ^a,b   Van Der Meel, R ^a   Storm, G ^a   Schiffelers, R M ^a,b  

^a UTRECHT UNIVERSITY   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Angiogenesis; Liposome; LPD particle; RGD; siRNA

Indexed keywords

ANGIOGENESIS; ANGIOGENIC PROCESS; ARG GLY ASPS; CANCER THERAPY; DNA CONTENT; ENHANCED UPTAKE; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; INTEGRINS; NON-TARGETED; PEGYLATION; RGD; RNA INTERFERENCE; SHORT INTERFERING RNA (SIRNA); SIRNA; SIRNA DELIVERY; SMALL INTERFERING RNA; TARGETED DELIVERY; TUMOR GROWTH; VASCULAR ENDOTHELIAL GROWTH FACTOR; VEGFR-2;

DNA; ENDOTHELIAL CELLS; LIPOSOMES; ONCOLOGY; OPTIMIZATION; TUMORS;

RNA;

DNA; LIPOSOME; POLYCATION; PROTAMINE; SMALL INTERFERING RNA; VASCULOTROPIN RECEPTOR 2;

ANIMAL CELL; ARTICLE; COMPLEX FORMATION; CONTROLLED STUDY; DNA CONTENT; ENDOTHELIUM CELL; GENE SILENCING; HUMAN; HUMAN CELL; IN VIVO GENE TRANSFER; MOUSE; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA INTERFERENCE; UMBILICAL VEIN ENDOTHELIAL CELL;

ANIMALS; BLOTTING, WESTERN; CELL CULTURE TECHNIQUES; DNA; DRUG CARRIERS; ENDOTHELIAL CELLS; GENE SILENCING; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; LIPOSOMES; MICE; NEOVASCULARIZATION, PATHOLOGIC; PARTICLE SIZE; POLYAMINES; RNA, SMALL INTERFERING; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84861691601     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2011.09.080     Document Type: Article

References (48)

1. J. Folkman Tumor angiogenesis: therapeutic implications N. Engl. J. Med. 285 21 1971 1182 1186
2. J. Folkman, E. Merler, C. Abernathy, and G. Williams Isolation of a tumor factor responsible for angiogenesis J. Exp. Med. 133 2 1971 275 288
3. J. Folkman Tumor angiogenesis factor Cancer Res. 34 8 1974 2109 2113
4. J. Folkman Angiogenesis: an organizing principle for drug discovery? Nat. Rev. Drug Discov. 6 4 2007 273 286
5. M. Papetti, and I.M. Herman Mechanisms of normal and tumor-derived angiogenesis Am. J. Physiol. Cell Physiol. 282 5 2002 C947 C970
6. M. Shibuya, and L. Claesson-Welsh Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis Exp. Cell Res. 312 5 2006 549 560
7. J.R. Roskoski Vascular endothelial growth factor (VEGF) signaling in tumor progression Crit. Rev. Oncol. Hematol. 62 3 2007 179 213
8. D. Shweiki, A. Itin, D. Soffer, and E. Keshet Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis Nature 359 6398 1992 843 845
9. D.J. Nolan, A. Ciarrocchi, A.S. Mellick, J.S. Jaggi, K. Bambino, S. Gupta, E. Heikamp, M.R. McDevitt, D.A. Scheinberg, R. Benezra, and V. Mittal Bone marrow-derived endothelial progenitor cells are a major determinant of nascent tumor neovascularization Genes Dev. 21 12 2007 1546 1558
10. A.-K. Olsson, A. Dimberg, J. Kreuger, and L. Claesson-Welsh VEGF receptor signalling? In control of vascular function Nat. Rev. Mol. Cell Biol. 7 5 2006 359 371
11. R. van der Meel, M.H. Symons, R. Kudernatsch, R.J. Kok, R.M. Schiffelers, G. Storm, W.M. Gallagher, and A.T. Byrne The VEGF/Rho GTPase signalling pathway: a promising target for anti-angiogenic/anti-invasion therapy Drug Discov. Today 16 5-6 2011 219 228
12. J.C. Yang, L. Haworth, R.M. Sherry, P. Hwu, D.J. Schwartzentruber, S.L. Topalian, S.M. Steinberg, H.X. Chen, and S.A. Rosenberg A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer N. Engl. J. Med. 349 5 2003 427 434
13. J. Holash, S. Davis, N. Papadopoulos, S.D. Croll, L. Ho, M. Russell, P. Boland, R. Leidich, D. Hylton, E. Burova, E. Ioffe, T. Huang, C. Radziejewski, K. Bailey, J.P. Fandl, T. Daly, S.J. Wiegand, G.D. Yancopoulos, and J.S. Rudge VEGF-Trap: a VEGF blocker with potent antitumor effects Proc. Natl. Acad. Sci. U. S. A. 99 17 2002 11393 11398
14. D.B. Mendel, A.D. Laird, X. Xin, S.G. Louie, J.G. Christensen, G. Li, R.E. Schreck, T.J. Abrams, T.J. Ngai, L.B. Lee, L.J. Murray, J. Carver, E. Chan, K.G. Moss, J.Ã. Haznedar, J. Sukbuntherng, R.A. Blake, L. Sun, C. Tang, T. Miller, S. Shirazian, G. McMahon, and J.M. Cherrington In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors Clin. Cancer Res. 9 1 2003 327 337
15. K.M. Cook, and W.D. Figg Angiogenesis inhibitors: current strategies and future prospects CA Cancer J. Clin. 60 4 2010 222 243
16. D. Bumcrot, M. Manoharan, V. Koteliansky, and D.W. Sah RNAi therapeutics: a potential new class of pharmaceutical drugs Nat. Chem. Biol. 2 12 2006 711 719
17. A. Fire, S. Xu, M.K. Montgomery, S.A. Kostas, S.E. Driver, and C.C. Mello Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans Nature 391 6669 1998 806 811
18. D. Castanotto, and J.J. Rossi The promises and pitfalls of RNA-interference-based therapeutics Nature 457 7228 2009 426 433
19. R.M. Schiffelers, M.C. Woodle, and P. Scaria Pharmaceutical prospects for RNA interference Pharm. Res. 21 1 2004 1 7
20. R.M. Schiffelers, I. van Rooy, and G. Storm siRNA-mediated inhibition of angiogenesis Expert. Opin. Biol. Ther. 5 3 2005 359 368
21. A.R. de Fougerolles Delivery vehicles for small interfering RNA in vivo Hum. Gene Ther. 19 2 2008 125 132
22. T.S. Zimmermann, A.C.H. Lee, A. Akinc, B. Bramlage, D. Bumcrot, M.N. Fedoruk, J. Harborth, J.A. Heyes, L.B. Jeffs, M. John, A.D. Judge, K. Lam, K. McClintock, L.V. Nechev, L.R. Palmer, T. Racie, I. Röhl, S. Seiffert, S. Shanmugam, V. Sood, J.r. Soutschek, I. Toudjarska, A.J. Wheat, E. Yaworski, W. Zedalis, V. Koteliansky, M. Manoharan, H.-P. Vornlocher, and I. MacLachlan RNAi-mediated gene silencing in non-human primates Nature 441 7089 2006 111 114
23. P. Vader, L. van der Aa, J. Engbersen, G. Storm, and R. Schiffelers Disulfide-based poly(amido amine)s for siRNA delivery: effects of structure on siRNA complexation, cellular uptake, gene silencing and toxicity Pharm. Res. 28 5 2011 1013 1022
24. M.E. Davis The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: from concept to clinic Mol. Pharm. 6 3 2009 659 668
25. A.K. Varkouhi, R.J. Verheul, R.M. Schiffelers, T. Lammers, G. Storm, and W.E. Hennink Gene silencing activity of siRNA polyplexes based on thiolated N,N,N-trimethylated chitosan Bioconjug. Chem. 21 12 2010 2339 2346
26. S.-D. Li, and L. Huang Surface-modified LPD nanoparticles for tumor targeting Ann. N. Y. Acad. Sci. 1082 1 2006 1 8
27. S. Li, M.A. Rizzo, S. Bhattacharya, and L. Huang Characterization of cationic lipid-protamine-DNA (LPD) complexes for intravenous gene delivery Gene Ther. 5 7 1998 930 937
28. S. Li, and L. Huang In vivo gene transfer via intravenous administration of cationic lipid-protamine-DNA (LPD) complexes Gene Ther. 4 9 1997 891 900
29. S.-D. Li, and L. Huang Targeted delivery of antisense oligodeoxynucleotide and small interference RNA into lung cancer cells Mol. Pharm. 3 5 2006 579 588
30. S.-D. Li, Y.-C. Chen, M.J. Hackett, and L. Huang Tumor-targeted delivery of siRNA by self-assembled nanoparticles Mol. Ther. 16 1 2007 163 169
31. S.-D. Li, and L. Huang Nanoparticles evading the reticuloendothelial system: role of the supported bilayer BBA-Biomembranes 1788 10 2009 2259 2266
32. R.M. Schiffelers, A.J. Mixson, A.M. Ansari, M.H.A.M. Fens, Q. Tang, Q. Zhou, J. Xu, G. Molema, P.Y. Lu, P.V. Scaria, G. Storm, and M.C. Woodle Transporting silence: design of carriers for siRNA to angiogenic endothelium J. Control. Release 109 1-3 2005 5 14
33. X.-L. Wang, R. Xu, X. Wu, D. Gillespie, R. Jensen, and Z.-R. Lu Targeted systemic delivery of a therapeutic siRNA with a multifunctional carrier controls tumor proliferation in mice Mol. Pharm. 6 3 2009 738 746
34. J. Jiang, S.-j. Yang, J.-c. Wang, L.-j. Yang, Z.-z. Xu, T. Yang, X.-y. Liu, and Q. Zhang Sequential treatment of drug-resistant tumors with RGD-modified liposomes containing siRNA or doxorubicin Eur. J. Pharm. Biopharm. 76 2 2010 170 178
35. R.M. Schiffelers, A. Ansari, J. Xu, Q. Zhou, Q. Tang, G. Storm, G. Molema, P.Y. Lu, P.V. Scaria, and M.C. Woodle Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle Nucleic Acids Res. 32 19 2004 e149
36. L. Huang, B. Sullenger, and R. Juliano The role of carrier size in the pharmacodynamics of antisense and siRNA oligonucleotides J. Drug Target. 18 8 2010 567 574
37. K. Maruyama Intracellular targeting delivery of liposomal drugs to solid tumors based on EPR effects Adv. Drug Deliv. Rev. 63 3 2011 161 169
38. D. Liu, A. Mori, and L. Huang Role of liposome size and RES blockade in controlling biodistribution and tumor uptake of GM1-containing liposomes BBA-Biomembranes 1104 1 1992 95 101
39. G. Thurston, J.W. McLean, M. Rizen, P. Baluk, A. Haskell, T.J. Murphy, D. Hanahan, and D.M. McDonald Cationic liposomes target angiogenic endothelial cells in tumors and chronic inflammation in mice J. Clin. Invest. 101 7 1998 1401 1413
40. S. Li, W.-C. Tseng, D.B. Stolz, S.-P. Wu, S.C. Watkins, and L. Huang Dynamic changes in the characteristics of cationic lipidic vectors after exposure to mouse serum: implications for intravenous lipofection Gene Ther. 6 4 1999 585 594
41. K. Braeckmans, K. Buyens, W. Bouquet, C. Vervaet, P. Joye, F.D. Vos, L. Plawinski, L.c. Doeuvre, E. Angles-Cano, N.N. Sanders, J. Demeester, and S.C.D. Smedt Sizing nanomatter in biological fluids by fluorescence single particle tracking Nano Lett. 10 11 2010 4435 4442
42. S.-D. Li, and L. Huang Stealth nanoparticles: high density but sheddable PEG is a key for tumor targeting J. Control. Release 145 3 2010 178 181
43. A.L. Klibanov, K. Maruyama, V.P. Torchilin, and L. Huang Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes FEBS Lett. 268 1 1990 235 237
44. P.S. Uster, T.M. Allen, B.E. Daniel, C.J. Mendez, M.S. Newman, and G.Z. Zhu Insertion of poly(ethylene glycol) derivatized phospholipid into pre-formed liposomes results in prolonged in vivo circulation time FEBS Lett. 386 2-3 1996 243 246
45. K. Sou, T. Endo, S. Takeoka, and E. Tsuchida Poly(ethylene glycol)-modification of the phospholipid vesicles by using the spontaneous incorporation of poly(ethylene glycol)-lipid into the vesicles Bioconjug. Chem. 11 3 2000 372 379
46. M.C. Woodle, L.R. Collins, E. Sponsler, N. Kossovsky, D. Papahadjopoulos, and F.J. Martin Sterically stabilized liposomes. Reduction in electrophoretic mobility but not electrostatic surface potential Biophys. J. 61 4 1992 902 910
47. K. Temming, R.M. Schiffelers, G. Molema, and R.J. Kok RGD-based strategies for selective delivery of therapeutics and imaging agents to the tumour vasculature Drug Resist. Updat. 8 6 2005 381 402
48. A. Fakhari, A. Baoum, T.J. Siahaan, K.B. Le, and C. Berkland Controlling ligand surface density optimizes nanoparticle binding to ICAM-1 J. Pharm. Sci. 100 3 2010 1045 1056